4D Molecular Therapeutics, Inc.
FDMTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, 4D Molecular Therapeutics, Inc. (FDMT) is listed under Biotechnology. With a market capitalization of $827.0M, it sits in small-cap territory. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Market Cap
$827.0M
Beta
2.73
P/E (TTM)
—
P/E (Fwd)
-3.66
EPS (TTM)
$-2.63
EPS (Fwd)
$-4.09
ROE
-43.3%
ROA
-25.1%
Cash
$361.3M
Total Debt
$39.2M
Free CF
-$90.8M
52W Change
114.8%
Annual Financials
Cash vs Debt
Where FDMT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, FDMT finished 44.35% above its 150-day moving average ($10.35) and 48.51% above its 200-day moving average ($10.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FDMT overbought or oversold?
At the September 3, 2026 close, FDMT's RSI(14) was 67.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $361.3M in cash and $39.2M in debt, FDMT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$90.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -43.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $3.1M (2022) to $85.2M (2025), reflecting a 2623% increase over the period.
4D Molecular Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, FDMT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for 4D Molecular Therapeutics, Inc. and its sector.